Open AccessA phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s
Author(s) -
Ariane L. Herrick,
Rohit Batta,
Kamilla Overbeck,
J. Raud,
Joanne Manning,
Andrea Murray,
Graham Dinsdale,
Göran Tornling
Publication year - 2022
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keac426
Subject(s) - medicine , placebo , agonist , clinical endpoint , randomized controlled trial , angiotensin ii , area under the curve , urology , gastroenterology , anesthesia , blood pressure , receptor , pathology , alternative medicine